# Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

> **NCT06476184** · PHASE3 · RECRUITING · sponsor: **ARCAGY/ GINECO GROUP** · enrollment: 250 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT06476184
- **Lead sponsor:** ARCAGY/ GINECO GROUP
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-30
- **Primary completion:** 2027-06
- **Final completion:** 2028-12
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2025-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06476184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06476184, "Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06476184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*